GT Biopharma Inc

OXIA

Company Profile

  • Business description

    GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

  • Contact

    315 Montgomery Street
    10th Floor
    San FranciscoCA94104
    USA

    https://www.gtbiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    1

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,777.9050.80-0.58%
CAC 407,871.36104.651.35%
DAX 4024,539.68332.771.37%
Dow JONES (US)44,440.82200.060.45%
FTSE 1008,864.9010.720.12%
HKSE23,892.32255.75-1.06%
NASDAQ20,607.60189.130.93%
Nikkei 22539,821.28132.470.33%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,261.7836.260.58%
S&P/ASX 2008,538.6052.10-0.61%
SSE Composite Index3,493.054.43-0.13%

Market Movers